Greenleaf Trust grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 7,527 shares of the medical research company’s stock after buying an additional 265 shares during the quarter. Greenleaf Trust’s holdings in Thermo Fisher Scientific were worth $1,429,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Covington Capital Management raised its position in shares of Thermo Fisher Scientific by 0.9% in the second quarter. Covington Capital Management now owns 2,144 shares of the medical research company’s stock valued at $374,000 after buying an additional 20 shares during the last quarter. Investment Centers of America Inc. raised its position in shares of Thermo Fisher Scientific by 1.6% in the second quarter. Investment Centers of America Inc. now owns 1,317 shares of the medical research company’s stock valued at $230,000 after buying an additional 21 shares during the last quarter. Fort Washington Investment Advisors Inc. OH raised its position in shares of Thermo Fisher Scientific by 0.4% in the second quarter. Fort Washington Investment Advisors Inc. OH now owns 6,250 shares of the medical research company’s stock valued at $1,090,000 after buying an additional 23 shares during the last quarter. Monetary Management Group Inc. raised its position in shares of Thermo Fisher Scientific by 0.6% in the second quarter. Monetary Management Group Inc. now owns 12,150 shares of the medical research company’s stock valued at $2,120,000 after buying an additional 75 shares during the last quarter. Finally, Millie Capital Management LLC increased its position in Thermo Fisher Scientific by 0.4% during the second quarter. Millie Capital Management LLC now owns 19,149 shares of the medical research company’s stock worth $3,341,000 after purchasing an additional 75 shares during the last quarter. Institutional investors and hedge funds own 86.11% of the company’s stock.

In related news, CEO Marc N. Casper sold 50,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $191.74, for a total value of $9,587,000.00. Following the completion of the transaction, the chief executive officer now owns 302,577 shares in the company, valued at $58,016,113.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Gregory J. Herrema sold 33,327 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $219.70, for a total transaction of $7,321,941.90. Following the completion of the transaction, the senior vice president now owns 60,471 shares of the company’s stock, valued at approximately $13,285,478.70. The disclosure for this sale can be found here. In the last three months, insiders sold 94,327 shares of company stock valued at $19,260,542. Insiders own 0.49% of the company’s stock.

Thermo Fisher Scientific Inc. (NYSE TMO) opened at $208.31 on Thursday. The company has a quick ratio of 0.92, a current ratio of 1.35 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 12 month low of $151.74 and a 12 month high of $226.44. The company has a market cap of $81,602.56, a P/E ratio of 37.20, a PEG ratio of 1.49 and a beta of 1.11.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, January 31st. The medical research company reported $2.79 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.66 by $0.13. Thermo Fisher Scientific had a net margin of 10.64% and a return on equity of 16.01%. The business had revenue of $6.05 billion during the quarter, compared to analyst estimates of $5.72 billion. During the same quarter last year, the firm posted $2.41 earnings per share. The business’s revenue for the quarter was up 22.1% compared to the same quarter last year. sell-side analysts expect that Thermo Fisher Scientific Inc. will post 10.81 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 16th. Stockholders of record on Thursday, March 15th will be paid a $0.17 dividend. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. The ex-dividend date is Wednesday, March 14th. This represents a $0.68 annualized dividend and a dividend yield of 0.33%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.71%.

Several research firms recently issued reports on TMO. Leerink Swann restated an “outperform” rating and set a $200.00 price objective (down from $216.00) on shares of Thermo Fisher Scientific in a research report on Monday, December 4th. Morgan Stanley raised their price objective on shares of Thermo Fisher Scientific from $223.00 to $227.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. BTIG Research began coverage on shares of Thermo Fisher Scientific in a research report on Friday, January 5th. They set a “buy” rating and a $230.00 price objective for the company. Zacks Investment Research upgraded shares of Thermo Fisher Scientific from a “sell” rating to a “hold” rating in a research report on Saturday, January 20th. Finally, Barclays raised their price objective on shares of Thermo Fisher Scientific from $225.00 to $245.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Two equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $220.50.

ILLEGAL ACTIVITY WARNING: “Greenleaf Trust Acquires 265 Shares of Thermo Fisher Scientific Inc. (TMO)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2018/02/15/greenleaf-trust-acquires-265-shares-of-thermo-fisher-scientific-inc-tmo.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.